These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 15046708)

  • 1. Antimetastatic drugs in prostate cancer.
    Chay CH; Cooper CC; Hellerstedt BA; Pienta KJ
    Clin Prostate Cancer; 2002 Jun; 1(1):14-9. PubMed ID: 15046708
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Angiogenesis-targeted therapies in prostate cancer.
    Lara PN; Twardowski P; Quinn DI
    Clin Prostate Cancer; 2004 Dec; 3(3):165-73. PubMed ID: 15636683
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel clinical trials in androgen-independent prostate cancer.
    Gulley J; Dahut W
    Clin Prostate Cancer; 2002 Jun; 1(1):51-7. PubMed ID: 15046713
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacotherapy of hormone refractory prostate cancer: new developments and challenges.
    Rosenbaum E; Carducci MA
    Expert Opin Pharmacother; 2003 Jun; 4(6):875-87. PubMed ID: 12783585
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Current trials using bone-targeting agents in prostate cancer.
    Tu SM; Lin SH
    Cancer J; 2008; 14(1):35-9. PubMed ID: 18303481
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Treatment options for hormone-refractory prostate cancer].
    Heidenreich A; Ohlmann CH
    Urologe A; 2005 Nov; 44(11):1303-4, 1306-14. PubMed ID: 16237541
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel therapeutic strategies in prostate cancer.
    Retter AS; Gulley JL; Dahut WL
    Cancer Biol Ther; 2004 Apr; 3(4):371-6. PubMed ID: 14726702
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [New targeted therapies in hormone-refractory prostate cancer].
    Oudard S; Banu E; Scotte F; Beuzeboc P; Guyader C; Medioni J
    Bull Cancer; 2007 Jul; 94(7 Suppl):F62-8. PubMed ID: 17845995
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Angiogenesis in prostate cancer: its role in disease progression and possible therapeutic approaches.
    van Moorselaar RJ; Voest EE
    Mol Cell Endocrinol; 2002 Nov; 197(1-2):239-50. PubMed ID: 12431818
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment options in androgen-independent prostate cancer.
    Lara PN; Meyers FJ
    Cancer Invest; 1999; 17(2):137-44. PubMed ID: 10071598
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment options in hormone-refractory prostate cancer: current and future approaches.
    Harris KA; Reese DM
    Drugs; 2001; 61(15):2177-92. PubMed ID: 11772129
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New drugs in prostate cancer.
    Armstrong AJ; Carducci MA
    Curr Opin Urol; 2006 May; 16(3):138-45. PubMed ID: 16679849
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The biology of hormone refractory prostate cancer. Why does it develop?
    Isaacs JT
    Urol Clin North Am; 1999 May; 26(2):263-73. PubMed ID: 10361549
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Management of prostate cancer. Part 3: metastatic disease.
    Shah J; Khaksar SJ; Sooriakumaran P
    Expert Rev Anticancer Ther; 2006 May; 6(5):813-21. PubMed ID: 16759171
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antiangiogenesis: a possible treatment option for prostate cancer?
    Longoria RL; Cox MC; Figg WD
    Clin Genitourin Cancer; 2005 Dec; 4(3):197-202. PubMed ID: 16425989
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Therapy of hormone refractory prostate cancer: new standards, new trends].
    Wülfing C; Bierer S; Bögemann M; Piechota H; Hertle L
    Aktuelle Urol; 2005 Aug; 36(4):342-8. PubMed ID: 16110408
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Management of patients with hormone refractory prostate cancer.
    Muthuramalingam SR; Patel K; Protheroe A
    Clin Oncol (R Coll Radiol); 2004 Dec; 16(8):505-16. PubMed ID: 15630842
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeted therapeutic approaches for hormone-refractory prostate cancer.
    Stavridi F; Karapanagiotou EM; Syrigos KN
    Cancer Treat Rev; 2010 Apr; 36(2):122-30. PubMed ID: 20106600
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Angiogenesis as a strategic target for prostate cancer therapy.
    Li Y; Cozzi PJ
    Med Res Rev; 2010 Jan; 30(1):23-66. PubMed ID: 19536866
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapeutic options for hormone-refractory prostate cancer in 2007.
    Hadaschik BA; Gleave ME
    Urol Oncol; 2007; 25(5):413-9. PubMed ID: 17826663
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.